Logo image of LIPO

LIPELLA PHARMACEUTICALS INC (LIPO) Stock Fundamental Analysis

NASDAQ:LIPO - Nasdaq - US53630L2097 - Common Stock - Currency: USD

2.29  -0.26 (-10.2%)

After market: 2.49 +0.2 (+8.73%)

Fundamental Rating

2

LIPO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While LIPO seems to be doing ok healthwise, there are quite some concerns on its profitability. LIPO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LIPO has reported negative net income.
LIPO had a negative operating cash flow in the past year.
In the past 5 years LIPO always reported negative net income.
In the past 5 years LIPO always reported negative operating cash flow.
LIPO Yearly Net Income VS EBIT VS OCF VS FCFLIPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

LIPO has a Return On Assets of -197.38%. This is amonst the worse of the industry: LIPO underperforms 88.83% of its industry peers.
Looking at the Return On Equity, with a value of -292.24%, LIPO is doing worse than 73.65% of the companies in the same industry.
Industry RankSector Rank
ROA -197.38%
ROE -292.24%
ROIC N/A
ROA(3y)-88.49%
ROA(5y)-64.8%
ROE(3y)-111.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LIPO Yearly ROA, ROE, ROICLIPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 50 -50 -100

1.3 Margins

LIPO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIPO Yearly Profit, Operating, Gross MarginsLIPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
LIPO has more shares outstanding than it did 1 year ago.
LIPO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LIPO Yearly Shares OutstandingLIPO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
LIPO Yearly Total Debt VS Total AssetsLIPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -12.31, we must say that LIPO is in the distress zone and has some risk of bankruptcy.
LIPO has a Altman-Z score of -12.31. This is in the lower half of the industry: LIPO underperforms 77.49% of its industry peers.
There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.31
ROIC/WACCN/A
WACC9.27%
LIPO Yearly LT Debt VS Equity VS FCFLIPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 2M -2M 4M

2.3 Liquidity

LIPO has a Current Ratio of 2.97. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
LIPO has a worse Current ratio (2.97) than 64.92% of its industry peers.
A Quick Ratio of 2.97 indicates that LIPO has no problem at all paying its short term obligations.
LIPO's Quick ratio of 2.97 is on the low side compared to the rest of the industry. LIPO is outperformed by 62.83% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
LIPO Yearly Current Assets VS Current LiabilitesLIPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for LIPO have decreased strongly by -468.36% in the last year.
Looking at the last year, LIPO shows a small growth in Revenue. The Revenue has grown by 0.75% in the last year.
Measured over the past years, LIPO shows a very negative growth in Revenue. The Revenue has been decreasing by -22.39% on average per year.
EPS 1Y (TTM)-468.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-460.29%
Revenue 1Y (TTM)0.75%
Revenue growth 3Y-22.39%
Revenue growth 5YN/A
Sales Q2Q%-22.77%

3.2 Future

LIPO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -42.38% yearly.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y-30.08%
EPS Next 2Y6.69%
EPS Next 3Y-42.38%
EPS Next 5YN/A
Revenue Next Year-17.65%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LIPO Yearly Revenue VS EstimatesLIPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200K 400K 600K 800K
LIPO Yearly EPS VS EstimatesLIPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LIPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIPO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIPO Price Earnings VS Forward Price EarningsLIPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIPO Per share dataLIPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

LIPO's earnings are expected to decrease with -42.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.69%
EPS Next 3Y-42.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LIPO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIPELLA PHARMACEUTICALS INC

NASDAQ:LIPO (3/7/2025, 8:00:02 PM)

After market: 2.49 +0.2 (+8.73%)

2.29

-0.26 (-10.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners6.1%
Inst Owner Change-79.99%
Ins Owners24.35%
Ins Owner Change0%
Market Cap2.77M
Analysts82.86
Price Target10.2 (345.41%)
Short Float %23.76%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.73
P/FCF N/A
P/OCF N/A
P/B 1.9
P/tB 1.9
EV/EBITDA N/A
EPS(TTM)-4.4
EYN/A
EPS(NY)-5.3
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-3.05
OCFYN/A
SpS0.4
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -197.38%
ROE -292.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.49%
ROA(5y)-64.8%
ROE(3y)-111.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -12.31
F-Score4
WACC9.27%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-468.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-460.29%
EPS Next Y-30.08%
EPS Next 2Y6.69%
EPS Next 3Y-42.38%
EPS Next 5YN/A
Revenue 1Y (TTM)0.75%
Revenue growth 3Y-22.39%
Revenue growth 5YN/A
Sales Q2Q%-22.77%
Revenue Next Year-17.65%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y0.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-78.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.1%
OCF growth 3YN/A
OCF growth 5YN/A